Cetrorelix (Cetrotide) Analog
Overview
Cetrorelix is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that acts as a competitive GnRH receptor antagonist. By binding to pituitary GnRH receptors, it rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion without the initial agonist flare seen with GnRH agonists. This property makes it valuable for controlled ovarian stimulation protocols, where prevention of premature LH surges is critical for optimizing oocyte retrieval timing.
Key Research Findings
Cetrorelix acetate was approved by the FDA in 2000 for prevention of premature LH surges in women undergoing controlled ovarian stimulation. Multiple randomized controlled trials have demonstrated comparable pregnancy rates to GnRH agonist protocols while allowing shorter treatment duration and reduced gonadotropin requirements.
Subcutaneous injection
FDA Approved
Interested in Cetrorelix (Cetrotide) Analog?
Find a verified provider experienced with Cetrorelix (Cetrotide) Analog protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Cetrorelix (Cetrotide) Analog ProviderRelated Peptides
Leuprolide (Lupron)
FDA ApprovedA synthetic nonapeptide GnRH agonist approximately 15-fold more potent than native GnRH. After an initial stimulatory phase (flare effect) lasting 1-2 weeks, chronic leuprolide administration downregulates pituitary GnRH receptors, resulting in profound suppression of LH, FSH, and downstream sex steroids. This chemical castration effect is exploited in treating hormone-sensitive cancers, endometriosis, and precocious puberty.
Goserelin (Zoladex)
FDA ApprovedA synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug release over 1 or 3 months. Like other GnRH agonists, goserelin initially stimulates and then suppresses the HPG axis, reducing sex hormone production to castrate or postmenopausal levels. The implant formulation eliminates the need for repeated injections and ensures compliance.
Cetrorelix (Cetrotide)
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively blocks pituitary GnRH receptors, producing immediate and dose-dependent suppression of LH and FSH without the initial flare effect seen with GnRH agonists. Cetrorelix prevents premature LH surges during controlled ovarian stimulation in IVF, allowing precise timing of oocyte maturation and retrieval.
Ganirelix
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors on pituitary gonadotroph cells. Ganirelix rapidly suppresses LH secretion within hours of administration, preventing premature ovulation during assisted reproductive technology (ART) cycles. Its mechanism provides immediate suppression without the flare phase associated with GnRH agonists.